Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Blend (12mg)

Description

Fragment 176-191 & Mod GRF 1-29 & Ipamorelin Peptide Blend

Modified GRF 1-29 is a shortened derivative of Growth Hormone-Releasing Hormone (GHRH). Unlike the natural full-length hormone, it contains only 29 amino acids, with four residues altered to improve stability. These changes make the molecule less vulnerable to breakdown by dipeptidyl peptidase-4 (DPP-4), which may extend its circulating time and improve overall pharmacokinetic properties.(1)

Ipamorelin is a synthetic five-amino-acid peptide classified as a growth hormone secretagogue receptor (GHSR) agonist. It is derived from earlier GHRP compounds and is thought to have minimal to no opioid receptor activity. Instead, it is believed to act primarily on ghrelin receptors (GHS-R1a), which are involved in stimulating growth hormone release.

Fragment 176-191 is a small segment of human growth hormone often referred to as a “fat-targeting” peptide. It consists of 16 amino acids, including a modified version of the 177–191 region of hGH with an added tyrosine at the N-terminus. It is also known as AOD 9604.(2)(3)

Chemical Composition

• Fragment 176-191: C78H125N23O23S2; 1817.12 g/mol
• Mod GRF 1-29: C152H252N44O42; 3367.9 g/mol
• Ipamorelin: C38H49N9O5; 711.8 g/mol

Alternative Names

• Mod GRF 1-29: also referred to as CJC-1295 without DAC
• Ipamorelin: also known as Ipamorelin acetate (IPA)
• Fragment 176-191: also called AOD 9604 or hGH lipolytic fragment

---

Research Overview

Fat metabolism and lipolysis

Among the three peptides, Fragment 176-191 is considered the primary compound linked to fat metabolism effects. Animal studies in obese mice have reported reductions in body weight and lipid levels after short-term administration. These effects were associated with increased expression of β3-adrenergic receptors, suggesting involvement of adrenergic pathways. However, experiments using receptor-deficient mice indicate that fat loss may still occur even without direct β3-AR involvement, possibly through increased energy expenditure and fat oxidation.(2)

Pituitary and growth hormone activity

Research reviews suggest that this peptide combination may influence body composition by both peripheral and central mechanisms. While Fragment 176-191 is thought to act mainly outside the central nervous system, Mod GRF 1-29 and Ipamorelin are believed to act on the pituitary to stimulate growth hormone release.(5)

Ipamorelin is thought to activate GHS-R1a receptors in the hypothalamus and pituitary, triggering intracellular signaling that leads to calcium release and subsequent secretion of growth hormone from somatotroph cells.

Mod GRF 1-29 is believed to act on GHRH receptors in the anterior pituitary. This activates the cAMP/PKA signaling cascade, increases intracellular calcium, and promotes growth hormone release. When used together with GHSR agonists like Ipamorelin, the effect is theorized to be synergistic, potentially increasing overall GH output.

Body weight and metabolic studies

A 2004 clinical study involving obese participants reported that Fragment 176-191 administration over 12 weeks led to modest reductions in body weight, particularly at lower doses, along with improvements in metabolic markers such as cholesterol and glucose handling.(6)

Tissue and cartilage research

Animal studies in rabbits have suggested that Fragment 176-191, especially when combined with hyaluronic acid, may support improved cartilage outcomes compared to either treatment alone, although these findings are preclinical.(7)

Bone and muscle effects

Ipamorelin has been studied in animal models for potential effects on bone density and muscle preservation under catabolic conditions. Some findings suggest it may help preserve bone mineral content and support skeletal strength, as measured in rodent experiments using imaging techniques like DEXA and pQCT.(8)(9)

Appetite and weight gain effects

Because Ipamorelin interacts with ghrelin receptors, it may also influence appetite regulation. Some animal studies suggest increased food intake and body weight gain, potentially linked to changes in leptin and energy balance signaling. In these models, body fat increases were also observed alongside overall weight gain.(10)

---

Note: This blend is typically described in literature as intended for laboratory or research use only and not for clinical or human application.